SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cambridge Heart (CAMH)-What is this???
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: James Silverman who wrote (12)4/3/1998 12:28:00 AM
From: John Zwiener  Read Replies (1) of 33
 
Haven't posted here for a while since no really new news. But now we are approaching report time. If you remember, the first attempt to run a trial for labelling approval to say something like "the finding of
t-alternans waves is correlated with an 85% risk of sudden death within one year (the patient is a candidate for a pacemaker)". That first trial was not able to accrue enough patients due to the trial design, and the location of the studies (the centers would immediately cath the patients preventing timely use of the instrument).

Now this time around, it looks like they have completed the study, or are getting close to it. If this study is anything like the smaller, scientific studies have continued to be, the results should be good. I think they are scheduled to present data in a month or two. Worth looking at again if you haven't lately.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News